2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic review
2021
Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology
Uhlig J, Mehta S, Case MD, Dhanasopon A, Blasberg J, Homer RJ, Solomon SB, Kim HS. Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology. Journal Of Vascular And Interventional Radiology 2021, 32: 1022-1028.e4. PMID: 33811997, DOI: 10.1016/j.jvir.2021.02.025.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyStage I lung cancerI lung cancerOverall survivalHistological subtypesNeuroendocrine tumorsCell carcinomaLung cancerThermal ablationPropensity scoreMost histological subtypesNational Cancer DatabaseSignificant OS differenceAmerican Joint CommitteeLarge cell carcinomaSmall cell carcinomaHigher overall survivalSquamous cell carcinomaLung cancer histologyLung cancer variesSmall neuroendocrine tumorsMore comorbiditiesTA patientsCancer variesInitial treatment
2020
Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis.
Wu X, Uhlig J, Blasberg J, Gettinger S, Suh R, Solomon S, Kim K. Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis. Journal Of Clinical Oncology 2020, 38: e21061-e21061. DOI: 10.1200/jco.2020.38.15_suppl.e21061.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyIncremental cost-effectiveness ratioStage I non-small cell lung cancerOne-way sensitivity analysesCell lung cancerBody radiotherapyRecurrence riskLung cancerHealth benefitsStage I NSCLC patientsLong-term prospective trialsPerfect healthAnnual recurrence riskHealth care sector perspectiveShort-term complicationsSensitivity analysisLong-term surveillanceThermal ablationWeeks of lifeCost-effectiveness analysisCost-effectiveness ratioDeterministic sensitivity analysesMedicare billing dataMultiple sensitivity analyses3:18 PM Abstract No. 148 Current United States nationwide utilization of thermal ablation for lung cancer
Uhlig J, Case M, Gettinger S, Blasberg J, Boffa D, Kim K. 3:18 PM Abstract No. 148 Current United States nationwide utilization of thermal ablation for lung cancer. Journal Of Vascular And Interventional Radiology 2020, 31: s70. DOI: 10.1016/j.jvir.2019.12.182.Peer-Reviewed Original Research
2018
Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study.
Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study. Radiology 2018, 289: 862-870. PMID: 30226453, DOI: 10.1148/radiol.2018180979.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage 1 non-small cell lung cancerStereotactic radiation therapyCell lung cancerOverall survivalLung cancerThermal ablationRadiation therapySurvival ratePropensity score-matched cohortUnplanned hospital readmission ratesNational Cancer DatabaseUnplanned hospital readmissionOverall survival rateHospital readmission ratesSmaller tumor sizeMore comorbiditiesReadmission ratesHospital readmissionRetrospective studyTumor sizePotential confoundersCancer DatabasePrimary treatmentPatients